Meeting
2013 ASCO Annual Meeting
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).
Authors
Lei Chen
Novartis Pharmaceuticals, East Hanover, NJ
Lei Chen , Annie Guérin , Eric Q. Wu , Katherine Dea , Stuart L. Goldberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7093)
DOI
10.1200/jco.2013.31.15_suppl.7093
Abstract #
7093
Poster Bd #
41E
Abstract Disclosures
Similar Posters
First Author: Ronald J. Rieder
Poster
2013 ASCO Annual Meeting
Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network.
First Author: Kathryn S. Kolibaba
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
Poster
2023 ASCO Annual Meeting
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
First Author: Tony Varughese